Dissecting Tumor Intrinsic and Immune Drivers of Resistance to Therapy in Non-Small Cell Lung Cancer


Damon Runyon - Mark Foundation Physician-Scientist (2020-Present)

Natalie Vokes, MD, The University of Texas MD Anderson Cancer Center

Natalie Vokes, MD

The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the development of immune-activating checkpoint inhibitors, given alone or with chemotherapy. However, most patients’ tumors eventually develop resistance to these drugs. Dr. Vokes is investigating this process by collecting data on the genetic and immune features of pre- and post-treatment tumors. She will then use computational algorithms to integrate these features into a model that predicts which patients are likely to respond to checkpoint inhibitor therapy and also sheds light on the difference between therapy given alone or with chemotherapy. A better understanding of how tumors evolve resistance will guide the design of more effective therapies for all patients and improve therapy selection for individuals.

Content courtesy of Damon Runyon Cancer Research Foundation

PUBLISHED RESEARCH

Reardon B, Moore ND, Moore NS, Kofman E, AlDubayan SH, Cheung ATM, Conway J, Elmarakeby H, Imamovic A, Kamran SC, Keenan T, Keliher D, Konieczkowski DJ, Liu D, Mouw KW, Park J, Vokes NI , Dietlein F, Van Allen EM. Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. Nat. Cancer. 2021.

Bakouny Z, Sadagopan A, Ravi P, Metaferia NY, Li J, AbuHammad S, Tang S, Denize T, Garner ER, Gao X, Braun DA, Hirsch L, Steinharter JA, Bouchard G, Walton E, West D, Labaki C, Dudani S, Gan CL, Sethunath V, Carvalho FLF, Imamovic A, Ricker C, Vokes NI, Nyman J, Berchuck JE, Park J, Hirsch MS, Haq R, Lee GSM, McGregor BA, Chang SL, Feldman AS, Wu CJ, McDermott DF, Heng DYC, Signoretti S, Van Allen EM, Choueiri TK, Viswanathan SR. Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Reports. 2022.

Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, Sholl L, Heymach JV, Nishino M, Van Allen EM, Jänne PA. Concurrent TP53 mutations facilitate resistance evolution in EGFR mutant lung adenocarcinoma. J Thorac Oncol. 2022.

BACK TO OUR PORTFOLIO